Solventum (NYSE:SOLV) Posts Earnings Results, Beats Estimates By $0.11 EPS

Solventum (NYSE:SOLV) posted its quarterly earnings data on Thursday. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.34 by $0.11, FiscalAI reports. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The company had revenue of $1.95 billion for the quarter, compared to the consensus estimate of $1.93 billion.

Here are the key takeaways from Solventum’s conference call:

• Q3 sales were $1.95 billion, down 7% reported and 2.8% organically, including a 630-basis-point headwind from the planned reversal of ERP-related advance orders. Management said normalized organic growth was about 4%; EPS was $1.45, including an estimated $0.35 impact from the timing reversal.
• Solventum raised its 2026 outlook, now expecting organic sales growth toward the high end of its 2.5%–3% range and EPS of $7.20–$7.30, up from $7.10–$7.20. Operating margin is expected toward the high end of its 22.2%–22.7% range.
• The company completed its largest ERP cutover and said its separation from 3M is more than 90% complete, with the remaining transition services expected to end by the close of 2027. A renegotiated supply agreement also removes a previously anticipated 100-basis-point gross-margin headwind beginning in 2027; management expects separation costs to step down, supporting free cash flow.
• Solventum is evaluating a sale or spin-off of Health Information Systems (HIS), with timing and structure still undecided. Management estimates the separation would cause about 400 basis points of annualized net operating margin dilution, though it expects to use proceeds first to pay down debt and then return most remaining proceeds to shareholders.
• Management highlighted growth opportunities from underpenetrated products, new launches, and acquisitions, including V.A.C. wound therapy and Acera. Acera grew 35% and had its best quarter on record, while the company said its combined-use clearance for Restrata and V.A.C. enables joint marketing.

Solventum Stock Performance

Solventum stock traded down $2.44 during midday trading on Thursday, hitting $86.91. The stock had a trading volume of 1,880,645 shares, compared to its average volume of 1,303,519. The firm’s fifty day moving average is $87.75 and its two-hundred day moving average is $78.64. The company has a market capitalization of $14.79 billion, a PE ratio of 10.63, a P/E/G ratio of 1.24 and a beta of 0.69. Solventum has a 52-week low of $62.38 and a 52-week high of $94.16. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00.

Wall Street Analyst Weigh In

SOLV has been the topic of several recent research reports. Mizuho set a $113.00 price target on shares of Solventum in a research report on Thursday, August 6th. Stifel Nicolaus boosted their price objective on shares of Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Benchmark restated a “buy” rating on shares of Solventum in a research note on Thursday, October 8th. Wall Street Zen raised Solventum from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. Finally, Wedbush lifted their target price on Solventum from $94.00 to $101.00 and gave the company an “outperform” rating in a research report on Thursday, August 6th. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.55.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Adjusted earnings were $1.45 per share, ahead of analyst estimates of $1.34–$1.35, and revenue of $1.95 billion also topped expectations. Solventum raised its FY2026 adjusted EPS outlook to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Reports Third Quarter 2026 Financial Results
• Negative Sentiment: Reported sales fell 7.0% year over year, while organic sales declined 2.8%. The company attributed the organic decrease partly to a 630-basis-point impact from customers’ advance orders in the prior quarter ahead of an ERP system cutover. Coverage also described the quarter as a loss on a reported basis, despite the adjusted earnings beat. Solventum Posts Q3 Loss; Raises FY26 Adjusted EPS Outlook
• Negative Sentiment: Higher raw-material costs remain a concern, potentially tempering the benefit of growth investments and cost-saving efforts. Here’s Why You Should Hold Solventum Stock in Your Portfolio for Now

About Solventum

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.